Puma Biotechnology Reports Q3 2026 Results with Revenue Growth Amidst China Royalty Reductions
Puma Biotechnology (PBYI) reported third-quarter 2026 total revenue of $55.1 million, primarily driven by $54.1 million in net product revenue from NERLYNX. While net product revenue grew compared to the same period last year, GAAP net income fell to $6 million ($0.11 per diluted share) from $8.8 million in Q3 2025. The company faced a significant royalty reduction in China due to generic competition reaching specific market share thresholds. Despite challenges in U.S. demand and Chinese royalties, the company demonstrated financial strength by maintaining zero long-term debt and increasing its cash position to $108.5 million. Management raised its full-year 2026 net income guidance to a range of $20 million to $22 million, citing continued financial discipline, even as they narrowed product revenue guidance slightly.
Tickers: $PBYI
Topics: net income product sales revenue royalty income